

Triterpenoid CDDO-Methyl Ester Inhibits the Janus-Activated Kinase-1 (JAK1)→Signal Transducer and Activator of Transcription-3 (STAT3) Pathway by Direct Inhibition of JAK1 and STAT3

Rehan Ahmad,¹ Deepak Raina,¹ Colin Meyer,² and Donald Kufe¹

¹Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts and ²Reata Pharmaceuticals, Inc., Dallas, Texas

Abstract

The C-28 methyl ester of the oleanane triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO-Me) induces apoptosis of human cancer cells by disrupting redox balance and is in clinical trials. CDDO-Me contains α,β -unsaturated carbonyl groups that form reversible adducts with thiol nucleophiles. The present studies show that CDDO-Me blocks interleukin-6 (IL-6)-induced and constitutive activation of the Janus-activated kinase 1 (JAK1) in cells. In support of a direct mechanism, CDDO-Me forms adducts with JAK1 at Cys¹⁰⁷⁷ in the kinase domain and inhibits JAK1 activity. In concert with these results, CDDO-Me blocked IL-6-induced and constitutive activation of signal transducer and activator of transcription 3 (STAT3). Moreover, we show that CDDO-Me (a) binds directly to STAT3 by a mechanism dependent on the alkylation of Cys²⁵⁹ and (b) inhibits the formation of STAT3 dimers. These findings indicate that CDDO-Me inhibits activation of the JAK1→STAT3 pathway by forming adducts with both JAK1 and STAT3. [Cancer Res 2008;68(8):2920–6]

Introduction

The synthetic oleanane triterpenoids are a new class of agents that have antiproliferative and proapoptotic activity (1). One of the synthetic oleanane triterpenoids, C-28 methyl ester of 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO-Me), is under study in phase I and II clinical trials for the treatment of patients with hematologic malignancies and solid tumors. In this regard, CDDO-Me and other derivatives with modifications at the C-28 position induce apoptosis of human myeloid leukemia (2–6), multiple myeloma (7–9), osteosarcoma (10), lung cancer (11, 12), breast cancer (13, 14), and pancreatic cancer (15). The synthetic oleanane triterpenoids activate the phase II response of cells at low nanomolar concentrations and thereby protect against oxidative stress by decreasing levels of reactive oxygen species (1). By contrast, at low micromolar concentrations, CDDO-Me and related derivatives induce apoptosis *in vitro* by increasing reactive oxygen species and decreasing intracellular glutathione (5, 7, 15, 16). How the synthetic oleanane triterpenoids disrupt redox balance and induce apoptosis at low micromolar concentrations is not known. However, structure-activity analysis has shown that α,β -unsaturated carbonyl groups on rings A and C confer Michael addition with a nucleophilic target (17, 18). In this context, nuclear factor κ B activates the transcription of diverse genes that regulate cell

survival (19), and CDDO directly inhibits the I κ B kinase β and thereby the nuclear factor- κ B pathway by interacting with Cys¹⁷⁹ in the I κ B kinase β activation loop (20, 21). These findings have indicated that CDDO-Me induces apoptosis, in part, by alkylating critical cysteines in proteins that regulate survival.

Members of the signal transducer and activator of transcription (STAT) family of transcription factors have, like nuclear factor κ B, been implicated in transformation, tumor cell survival, invasion, and metastasis (22). Activation of STAT3, in particular, has been detected in diverse hematologic malignancies and solid tumors (22–24) and induces transformation (25). STAT3 is also constitutively activated in immune cells in the tumor microenvironment (26). STAT3 is activated by Janus-activated kinase (JAK)-1 phosphorylation of the interleukin-6 (IL-6) receptor, recruitment of STAT3, and, in turn, phosphorylation of STAT3 (27). STAT3 then forms dimers that translocate to the nucleus and activate STAT3 target genes, which encode regulators of cell cycle progression (cyclin D1 and c-Myc) and inhibitors of apoptosis (survivin and Bcl-x_l; refs. 28, 29). The pattern of STAT3-induced gene expression is regulated by diverse signals that converge on JAK1 and STAT3 (27), indicating that both proteins are targets for inhibiting this pathway. Importantly, small-molecule inhibitors of the STAT3 pathway are effective as anticancer agents *in vitro* and in animal models (30, 31). Other studies have shown that the triterpenoids decrease pSTAT3 levels (9, 32, 33); however, the mechanistic basis for this response is not known.

The present results show that CDDO-Me directly inhibits IL-6-induced and constitutive JAK1 activity. The results also show that CDDO-Me directly blocks STAT3 signaling and the induction of growth and survival genes.

Materials and Methods

Cell culture. Human HeLa cervical cancer and MDA-MB-468 breast cancer cells were cultured in DMEM containing 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin, 100 μ g/mL streptomycin, and 2 mmol/L L-glutamine. Cells were treated with CDDO-Me (provided by Reata Pharmaceuticals) and human IL-6 (20 ng/mL; R&D Systems).

Subcellular fractionation. Nuclear fractions were prepared as described (34).

Immunoblot analysis. Lysates were analyzed by immunoblotting with antibodies against phospho-JAK1, phospho-JAK2 (Millipore), JAK1, JAK2, STAT3, I κ B α , cyclin D1, survivin (Santa Cruz Biotechnology), phospho-STAT3 (Cell Signaling Technology), STAT3 monoclonal antibody (BD Transduction Laboratory), lamin B (Calbiochem), and β -actin (Sigma). The immune complexes were detected with horseradish peroxidase-conjugated second antibodies and enhanced chemiluminescence (Amersham Biosciences).

JAK1 kinase assays. Soluble proteins were incubated with anti-JAK1 or anti-green fluorescent protein (GFP; Abcam) and precipitated with protein A/G beads. The immune complexes were incubated in kinase buffer

Requests for reprints: Donald Kufe, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Phone: 617-632-3141; E-mail: donald_kufe@dfci.harvard.edu.
©2008 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-07-3036

Figure 1. CDDO-Me inhibits IL-6-induced and constitutive JAK1 activity. *A* and *B*, HeLa cells were pretreated with 1 $\mu\text{mol/L}$ CDDO-Me for 6 h and then left unstimulated (*Control*) or stimulated with IL-6 for 15 min. Whole-cell lysates were subjected to immunoblotting with the indicated antibodies. *C*, MDA-MB-468 cells were treated with the indicated concentrations of CDDO-Me for 6 h. Lysates were immunoblotted with the indicated antibodies. *D*, MDA-MB-468 cells were treated with 1 $\mu\text{mol/L}$ CDDO-Me for the indicated times. Lysates were immunoblotted with the indicated antibodies.





Figure 2. CDDO-Me directly inhibits JAK1 activity. *A*, HeLa cells were left untreated as the control or stimulated with IL-6 for 15 min (*left*). MDA-MB-468 cells were analyzed without stimulation (*right*). Anti-JAK1 precipitates were incubated with GST-STAT3 and [γ - ^{32}P]ATP in the absence and presence of 1 $\mu\text{mol/L}$ CDDO-Me. The reaction products were analyzed by SDS-PAGE and autoradiography (*top*). The precipitates were also analyzed by immunoblotting with anti-JAK1 (*bottom*). *B*, MDA-MB-468 cells were transfected with GFP-JAK1. At 48 h after transfection, lysates were precipitated with anti-GFP. The precipitates were incubated with GST-STAT3 and [γ - ^{32}P]ATP in the absence and presence of 1 $\mu\text{mol/L}$ CDDO-Me. The reaction products were analyzed by SDS-PAGE and autoradiography (*top*). The precipitates were also analyzed by immunoblotting with anti-GFP (*bottom*). *C*, lysates from HeLa cells were incubated with biotin or CDDO-Me-biotin and then precipitated with streptavidin-Sepharose beads. The adsorbates were immunoblotted with anti-JAK1 and anti-JAK2 (*left*). Intact MDA-MB-468 cells were pretreated with the indicated concentrations of CDDO-Me for 2 h and then incubated with 1 $\mu\text{mol/L}$ CDDO-Me-biotin. Lysates were precipitated with streptavidin-Sepharose beads and the adsorbates were immunoblotted with anti-JAK1 (*right*). *D*, recombinant JAK1-KD or JAK1-KD(C1077A) was incubated with 1 $\mu\text{mol/L}$ CDDO-Me-biotin for 30 min. The complexes were isolated with streptavidin-Sepharose beads and the precipitates were subjected to immunoblotting with anti-JAK1 (*top*). Input of the proteins was determined by immunoblotting with anti-JAK1 (*bottom*).




Figure 3. CDDO-Me inhibits IL-6-induced STAT3 activation. *A* and *B*, HeLa cells were pretreated with the indicated concentrations of CDDO-Me for 6 h and then stimulated with IL-6 for 15 min. Whole-cell lysates were immunoblotted with the indicated antibodies (*A*). Nuclear lysates were immunoblotted with anti-STAT3 and, as controls for equal loading and purity, with antibodies against nuclear lamin B and cytosolic I κ B α (*B*). *WCL*, whole-cell lysate. *C*, HeLa cells were transfected with pSTAT3-Luc and SV40-Renilla-Luc. At 24 h after transfection, cells were pretreated with 1 $\mu\text{mol/L}$ CDDO-Me for 6 h, stimulated with IL-6 for 15 min, and then assayed for luciferase activity. *Columns*, mean fold activation relative to that obtained for the control (assigned a value of 1) from three separate experiments; *bars*, SD. *D*, HeLa cells were treated with 1 $\mu\text{mol/L}$ CDDO-Me for 2 h and then IL-6 was added for the indicated times. Lysates were immunoblotted with the indicated antibodies.




Figure 4. CDDO-Me inhibits constitutive activation of the STAT3 pathway. *A* and *B*, MDA-MB-468 cells were treated with the indicated concentrations of CDDO-Me for 6 h or 1 $\mu\text{mol/L}$ CDDO-Me for the indicated times. Whole-cell lysates were immunoblotted with the indicated antibodies (*A*). Nuclear lysates were immunoblotted with anti-STAT3 and, as controls for equal loading and purity, with antibodies against nuclear lamin B and cytosolic I κ B α (*B*). *C*, MDA-MB-468 cells were transfected with pSTAT3-Luc and SV40-Renilla-Luc. At 24 h after transfection, cells were treated with the indicated concentrations of CDDO-Me for 6 h and then assayed for luciferase activity. *Columns*, mean fold activation relative to that obtained for cells treated with 2 $\mu\text{mol/L}$ CDDO-Me (assigned a value of 1) from three separate experiments; *bars*, SD. *D*, MDA-MB-468 cells were left untreated or treated with 1 $\mu\text{mol/L}$ CDDO-Me for 6 h. Lysates were immunoblotted with the indicated antibodies.




Figure 5. CDDO-Me blocks dimerization of STAT3. *A* and *B*, HeLa cells were stimulated with IL-6 for 15 min (*A*). MDA-MB-468 cells were untreated (*B*). Lysates were immunoprecipitated with anti-STAT3 (polyclonal, anti-COOH-terminal). The precipitates were incubated with 0 or 1 $\mu\text{mol/L}$ CDDO-Me for 2 h, washed, suspended in nonreducing sample buffer, boiled for 5 min, and immunoblotted with anti-STAT3 (monoclonal, anti-NH₂-terminal). *C*, MDA-MB-468 cells were transfected with the empty pCMV vector or cotransfected with Flag-STAT3 and HA-STAT3. At 48 h after transfection, lysates were precipitated with anti-HA. The precipitates were incubated with 0 or 1 $\mu\text{mol/L}$ CDDO-Me for 2 h and then immunoblotted with the indicated antibodies.

[20 mmol/L Tris-HCl (pH 7.5), 10 mmol/L MgCl₂, and 100 $\mu\text{mol/L}$ ATP] with 1 μg of recombinant glutathione *S*-transferase (GST)-STAT3 and [γ -³²P]ATP (Perkin-Elmer Life Sciences), as described (35), in the absence and presence of 1 $\mu\text{mol/L}$ CDDO-Me for 30 min at 30°C. The reaction products were analyzed by SDS-PAGE and autoradiography.

Binding of CDDO-Me-biotin to JAK1 and STAT3. CDDO-Me and CDDO were biotinylated as described (36). Lysates were incubated with 1 $\mu\text{mol/L}$ biotin (Calbiochem) or CDDO-Me-biotin for 2 h, followed by addition of streptavidin-Sepharose beads (GE Healthcare) for 1 h. Alternatively, intact cells were pretreated with CDDO-Me for 2 h and then incubated with 1 $\mu\text{mol/L}$ CDDO-Me-biotin. Complexes were isolated with streptavidin-Sepharose beads. The beads were washed and then subjected to immunoblotting with anti-JAK1 or anti-STAT3. In other studies, recombinant GST-JAK1 kinase domain (KD; amino acids 870–1,152), GST-STAT3 or GST-JAK1-KD(C1077A), and GST-STAT3(C259A), generated by site-directed mutagenesis, were cleaved with thrombin to remove the GST moiety. The purified JAK1-KD and STAT3 proteins were incubated with 1 $\mu\text{mol/L}$ biotin, CDDO-Me-biotin, or CDDO-biotin for 30 min. Complexes were isolated with streptavidin-Sepharose beads and analyzed by immunoblotting with anti-JAK1 and anti-STAT3.

Luciferase assays. Cells were transfected with pSTAT3-Luc (Panomics) and SV40-Renilla-Luc (Promega) in the presence of Lipofectamine 2000 (Invitrogen). At 24 h after transfection, lysates were analyzed with the Dual Luciferase Assay Kit (Promega).

Analysis of STAT3 dimerization. Cell lysates were incubated with anti-STAT3 (Santa Cruz Biotechnology) and precipitated with protein A/G beads. The precipitates were immunoblotted with anti-STAT3 (BD Transduction Laboratories). In other studies, MDA-MB-468 cells were cotransfected with pCMV-STAT3-Flag and pCMV-STAT3-HA (30) in the

presence of Lipofectamine 2000 (Invitrogen). At 48 h after transfection, lysates were incubated with anti-hemagglutinin (HA; Sigma) and the precipitates analyzed by immunoblotting with anti-Flag (Sigma).

Results

CDDO-Me inhibits JAK1 activity. To determine whether CDDO-Me affects JAK signaling, we first studied HeLa cells that were stimulated with IL-6. Phospho-JAK1 levels were low to undetectable in control HeLa cells and were increased with IL-6 stimulation (Fig. 1*A*). Notably, treatment of the HeLa cells with CDDO-Me suppressed IL-6-induced JAK1 activation (Fig. 1*A*). IL-6 stimulation was also associated with increases in phospho-JAK2 levels (Fig. 1*B*). However, in contrast to JAK1, CDDO-Me treatment had no apparent effect on JAK2 activation (Fig. 1*B*). There was no detectable activation of JAK3 in the IL-6-stimulated HeLa cells (data not shown). In contrast to HeLa cells, JAK1 is constitutively activated in human MDA-MB-468 cells (Fig. 1*C*). Treatment of MDA-MB-468 cells with CDDO-Me was associated with down-regulation of phospho-JAK1 levels (Fig. 1*C*). Moreover, the effect of CDDO-Me on phospho-JAK1 was detectable within 2 hours of treatment (Fig. 1*D*). These findings indicate that CDDO-Me inhibits JAK1, but not JAK2, activation.

CDDO-Me interacts directly with JAK1. To further assess the effects of CDDO-Me, we immunoprecipitated JAK1 from control and IL-6-stimulated HeLa cells and performed *in vitro* kinase assays with GST-STAT3 as substrate. IL-6 stimulation was associated with increases in JAK1-mediated phosphorylation of STAT3 (Fig. 2*A, left*). However, addition of CDDO-Me to the reactions blocked STAT3 phosphorylation, indicating that CDDO-Me directly blocks JAK1 activity (Fig. 2*A, left*). *In vitro* kinase assays with constitutively activated JAK1 immunoprecipitated from MDA-MB-468 breast cancer cells also showed that addition of CDDO-Me to the reactions blocks JAK1-mediated phosphorylation of STAT3 (Fig. 2*A, right*). To confirm these findings, we expressed GFP-tagged JAK1 in MDA-MB-468 cells. Analysis of anti-GFP precipitates showed that phosphorylation of GST-STAT3 is inhibited by CDDO-Me (Fig. 2*B*). To determine whether CDDO-Me interacts with JAK1, lysates from HeLa cells were incubated with CDDO-Me conjugated to biotin. Analysis of the adsorbates by immunoblotting with anti-JAK1 showed binding to CDDO-Me and not biotin (Fig. 2*C, left*). By contrast, there was no detectable binding of CDDO-Me to JAK2 (Fig. 2*C, left*). Incubation of intact MDA-MB-468 cells showed binding of JAK1 to CDDO-Me-biotin and not biotin (Fig. 2*C, right*). In addition, pretreatment of intact cells with CDDO-Me competitively blocked binding of JAK1 to CDDO-Me-biotin (Fig. 2*C, right*). JAK1 contains a cysteine residue at position 1077 in the kinase domain that is not present in JAK2. Binding of CDDO-Me-biotin was detectable with purified recombinant JAK1-KD (Fig. 2*D*). By contrast, the formation of adducts was substantially decreased when recombinant JAK1-KD mutated at Cys¹⁰⁷⁷ was incubated with CDDO-Me-biotin (Fig. 2*D*). These findings indicate that CDDO-Me interacts directly with JAK1 on Cys¹⁰⁷⁷ and inhibits JAK1 activity.

CDDO-Me inhibits the IL-6-induced STAT3 pathway. JAK1 phosphorylates and thereby activates STAT3 for targeting to the nucleus (22, 27). In this context, IL-6 stimulation of HeLa cells was associated with increases in phospho-STAT3 levels (Fig. 3*A*). Treatment of the HeLa cells with CDDO-Me blocked IL-6-induced phospho-STAT3 (Fig. 3*A*). In addition, CDDO-Me blocked IL-6-induced targeting of pSTAT3 to the nucleus (Fig. 3*B*). Transfection of HeLa cells with a pSTAT3-luciferase (Luc) reporter showed that IL-6

stimulates STAT3-mediated transcription and that CDDO-Me inhibits this response (Fig. 3C). STAT3 activates transcription of the cyclin D1 and survivin genes. Consistent with inhibition of STAT3-mediated transcription, IL-6-induced increases in cyclin D and survivin expression were inhibited by CDDO-Me treatment (Fig. 3D). These results and our findings with JAK1 indicate that CDDO-Me blocks IL-6-induced activation of the JAK1→STAT3 pathway.

CDDO-Me blocks constitutive activation of the JAK1→STAT3 pathway. The JAK1→STAT3 pathway is constitutively activated in MDA-MB-468 breast cancer cells (37). Consistent with the results obtained in IL-6-stimulated HeLa cells, treatment of MDA-MB-468 cells with CDDO-Me down-regulated constitutive phosphorylation of STAT3 (Fig. 4A, left). Analysis of the kinetics of this response showed decreases in phospho-STAT3 levels within 2 hours of CDDO-Me treatment (Fig. 4A, right). Furthermore, CDDO-Me inhibited the constitutive nuclear localization of STAT3 in MDA-MB-468 cells (Fig. 4B). Constitutive activation of the pSTAT3-Luc reporter was inhibited by CDDO-Me (Fig. 4C). In addition, CDDO-Me treatment was associated with down-regulation of cyclin D1 and survivin expression (Fig. 4D). These results indicate that CDDO-Me blocks constitutive activation of the JAK1→STAT3 pathway in MDA-MB-468 cells.

CDDO-Me blocks STAT3 dimerization. JAK1-mediated phosphorylation of STAT3 is associated with the targeting of phospho-STAT3 dimers to the nucleus for activation of STAT3-dependent genes. Thus, IL-6 stimulation of HeLa cells results in the formation of STAT3 dimers (Fig. 5A). To determine if CDDO-Me affects STAT3 dimerization, lysates from IL-6-stimulated HeLa cells were incubated with CDDO-Me. The results show that CDDO-Me disrupts the STAT3 dimers (Fig. 5A). Constitutive STAT3 dimerization

in MDA-MB-468 cells was also disrupted by CDDO-Me (Fig. 5B). To confirm these results, we transfected MDA-MB-468 cells with HA-tagged STAT3 (HA-STAT3) and Flag-tagged STAT3 (Flag-STAT3). Immunoblot analysis of anti-HA precipitates with anti-Flag showed the formation of Flag-STAT3-HA-STAT3 dimers (Fig. 5C). Moreover, incubation of the anti-HA precipitates with CDDO-Me resulted in disruption of the Flag-STAT3-HA-STAT3 dimers (Fig. 5C). These results indicate that CDDO-Me blocks STAT3 dimerization.

CDDO-Me forms adducts with STAT3 that are dependent on Cys²⁵⁹. Incubation of HeLa cell lysates with CDDO-Me-biotin showed that CDDO-Me forms complexes with STAT3 (Fig. 6A, left). Incubation of intact MDA-MB-468 cells showed binding of STAT3 to CDDO-Me-biotin and not biotin (Fig. 6A, right). In addition, pretreatment of intact MDA-MB-468 cells with different concentrations of CDDO-Me showed inhibition of the binding of CDDO-Me-biotin to STAT3 (Fig. 6A, right). We also incubated recombinant STAT3 with CDDO-Me-biotin. Analysis of the adsorbates with anti-STAT3 showed that CDDO-Me interacts directly with STAT3 (Fig. 6B). The parent compound CDDO similarly formed direct complexes with recombinant STAT3 (Fig. 6B). By contrast, the interaction was blocked when recombinant STAT3(C259A) was incubated with CDDO-Me-biotin (Fig. 6C). These findings indicate that CDDO-Me inhibits STAT3 by direct alkylation of Cys²⁵⁹.

Discussion

The synthetic oleanane triterpenoids disrupt redox balance and thereby induce apoptosis at low micromolar concentrations (5, 7, 15, 16). The mechanism(s) responsible for such activity remain unclear. However, certain insights are being obtained from the




Figure 6. CDDO-Me binds directly to STAT3 at Cys²⁵⁹. *A*, HeLa cell lysates were incubated with 1 $\mu\text{mol/L}$ of biotin or CDDO-Me-biotin for 2 h. Streptavidin-Sepharose beads were then added for 1 h. The precipitates were immunoblotted with anti-STAT3 (left). Intact MDA-MB-468 cells were pretreated with the indicated concentrations of CDDO-Me for 2 h and then incubated with 1 $\mu\text{mol/L}$ CDDO-Me-biotin. Lysates were precipitated with streptavidin-Sepharose beads and the adsorbates were immunoblotted with anti-STAT3 (right). *B* and *C*, recombinant purified STAT3 was incubated with 1 $\mu\text{mol/L}$ biotin, CDDO-Me-biotin, or CDDO-biotin for 30 min (*B*). Recombinant STAT3 or STAT3(C259A) was incubated with 1 $\mu\text{mol/L}$ biotin or CDDO-Me-biotin for 30 min (*C*). Complexes were isolated with streptavidin beads and the precipitates were immunoblotted with anti-STAT3 (top). Input of the STAT3 proteins was assessed by immunoblotting with anti-STAT3 (bottom). *D*, schema depicting CDDO-Me inhibition of the JAK1→STAT3 pathway.

findings that the synthetic oleanane triterpenoids can confer Michael addition with nucleophilic targets (17, 18). In this regard, a direct interaction of a synthetic oleanane triterpenoid was found spectroscopically with thiol groups of the Keap1 sensor (18). Subsequent studies have shown that CDDO and its C-28 derivatives interact directly with I κ B kinase β at Cys¹⁷⁹ in the activation loop (20, 21). Otherwise, to our knowledge, there are no reports of CDDO or its derivatives forming adducts with other protein targets. The cyclopentenone prostaglandins also contain an α,β -unsaturated carbonyl moiety and react with the I κ B kinase β Cys¹⁷⁹ residue (38). However, few targets of the cyclopentenone prostaglandins have been identified to date, even when using an unbiased proteomic approach (39). Nonetheless, the findings that the cyclopentenone prostaglandins react with H-Ras (40), heat shock protein 90 (39), and estrogen receptor α (41) provide potential leads for additional targets of the synthetic oleanane triterpenoids.

Constitutive activation of STAT3 contributes to tumorigenesis by promoting proliferation and inhibiting apoptosis (42). Tyrosine phosphorylation of STAT3 confers dimerization through binding of the SH2 domain of one monomer to a P-pY-LKTK motif on the other STAT3 monomer (31, 43–45). The present results show that CDDO-Me inhibits IL-6–induced and constitutive JAK1 activity. The results support a model in which CDDO-Me binds directly to JAK1 at Cys¹⁰⁷⁷ in the kinase domain and thereby blocks JAK1 as an upstream effector of STAT3 phosphorylation (Fig. 6D). The triterpenoids have been shown to decrease pSTAT3 levels (9, 32, 33) and the present findings show that this response is associated with the direct inhibition of JAK1.

Dimerization of STAT3 is necessary for its activation and oncogenic function (25). STAT3 target genes confer diverse

processes of transformation, including proliferation, apoptosis, angiogenesis, and metastasis (46). In this regard, agents that inhibit STAT3 dimerization and activation exhibit antitumor activity (30, 31). Previous studies have shown that STAT3 dimerization is also mediated by interchain disulfide bridging involving Cys²⁵⁹ (37). Notably, the present results show that CDDO-Me disrupts STAT3 dimers. Moreover, we show that CDDO-Me binds directly to STAT3 by forming adducts with Cys²⁵⁹ (Fig. 6D). Thus, CDDO-Me–mediated disruption of STAT3 dimerization is consistent with alkylation of Cys²⁵⁹ and thereby loss of interchain bridging. CDDO-Me treatment was also associated with down-regulation of cyclin D1 and survivin, both encoded by STAT3 target genes. Notably, the inhibition of JAK1 would be sufficient to decrease STAT3 phosphorylation and dimerization. However, the results also show that CDDO-Me directly inhibits STAT3. These findings thus collectively indicate that CDDO-Me blocks the JAK1–STAT3 pathway by directly inhibiting both JAK1 and STAT3 (Fig. 6D).

Acknowledgments

Received 8/7/2007; revised 1/25/2008; accepted 2/7/2008.

Grant support: National Cancer Institute grants CA42802, CA100707, and CA98628.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Jiayuh Lin (Ohio State University) for providing the Flag-STAT3 and HA-STAT3 vectors, Dr. Robert Schreiber (Washington University) for the GFP-JAK1 vector, Dr. Nancy Reich (Stony Brook University) for the GST-STAT3 vector, and Dr. Ratna Ray (St. Louis University) for the Myc-JAK1 vector. D. Raina is a consultant to Reata.

References

- Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. *Nat Rev Cancer* 2007;7:357–69.
- Ito Y, Pandey P, Place A, et al. The novel triterpenoid CDDO induces apoptosis of human myeloid leukemia cells by a caspase-8 dependent mechanism. *Cell Growth Differ* 2000;11:261–7.
- Konopleva M, Tsao T, Ruvolo P, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. *Blood* 2002;99:326–35.
- Stadheim TA, Suh N, Ganju N, Sporn MB, Eastman A. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potentially enhances apoptosis induced by tumor necrosis factor in human leukemia cells. *J Biol Chem* 2002;277:16448–55.
- Ikedo T, Kimura F, Nakata Y, et al. Triterpenoid CDDO-Im down-regulates PML/RAR α expression in acute promyelocytic leukemia cells. *Cell Death Differ* 2005;12:523–31.
- Konopleva M, Tsao T, Estrov Z, et al. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. *Cancer Res* 2004;64:7927–35.
- Ikedo T, Nakata Y, Kimura F, et al. Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid. *Mol Cancer Ther* 2004;3:39–45.
- Chauhan D, Li G, Podar K, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. *Blood* 2004;103:3158–66.
- Liby K, Voong N, Williams CR, et al. The synthetic triterpenoid CDDO-imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. *Clin Cancer Res* 2006;12:4288–93.
- Ito Y, Pandey P, Sporn M, et al. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. *Mol Pharmacol* 2001;59:1094–9.
- Kim K, Lotan R, Yue P, et al. Identification of a novel synthetic triterpenoid, methyl-2-cyano-3, 12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. *Mol Cancer Ther* 2002;1:177–84.
- Zou W, Liu X, Yue P, et al. c-Jun NH₂-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate in human lung cancer cells. *Cancer Res* 2004;64:7570–8.
- Lapillonne H, Konopleva M, Tsao T, et al. Activation of peroxisome proliferator-activated receptor γ by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. *Cancer Res* 2003;63:5926–39.
- Hyer ML, Croxton R, Krajewska M, et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. *Cancer Res* 2005;65:4799–808.
- Samudio I, Konopleva M, Hail N, Jr., et al. 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. *J Biol Chem* 2005;280:36273–82.
- Ikedo T, Sporn M, Honda T, Gribble G, Kufe D. The novel triterpenoid CDDO induces apoptosis by disruption of intracellular redox balance. *Cancer Res* 2003;63:5551–8.
- Couch RD, Browning RG, Honda T, et al. Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. *Bioorg Med Chem Lett* 2005;15:2215–9.
- Dinkova-Kostova AT, Liby KT, Stephenson KK, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. *Proc Natl Acad Sci U S A* 2005;102:4584–9.
- Karin M, Lin A. NF- κ B at the crossroads of life and death. *Nat Immunol* 2002;3:221–7.
- Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me blocks the NF- κ B pathway by direct inhibition of IKK β on Cys-179. *J Biol Chem* 2006;281:35764–9.
- Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor- κ B activation through direct inhibition of I κ B kinase β . *Mol Cancer Ther* 2006;5:3232–9.
- Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. *Science* 2002;296:1653–5.
- Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. *Oncogene* 2000;19:2474–88.
- Dechow TN, Pedranzini L, Leitch A, et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. *Proc Natl Acad Sci U S A* 2004;101:10602–7.
- Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. *Cell* 1999;98:295–303.
- Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat Rev Immunol* 2007;7:41–51.
- Murray PJ. The JAK-STAT signaling pathway: input and output integration. *J Immunol* 2007;178:2623–9.

28. Alvarez JV, Febbo PG, Ramaswamy S, et al. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. *Cancer Res* 2005;65:5054–62.
29. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. *Cancer Res* 2006;66:3162–8.
30. Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. *Proc Natl Acad Sci U S A* 2005;102:4700–5.
31. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. *Proc Natl Acad Sci U S A* 2007;104:7391–6.
32. Liby K, Royce DB, Williams CR, et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. *Cancer Res* 2007;67:2414–9.
33. Ling X, Konopleva M, Zeng Z, et al. The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxolen-1,9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. *Cancer Res* 2007;67:4210–8.
34. Kharbanda S, Saleem A, Yuan Z-M, et al. Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53^{lyn} tyrosine kinase with p34^{cd2}. *Cancer Res* 1996;56:3617–21.
35. Kamakura S, Oishi K, Yoshimatsu T, et al. Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling. *Nat Cell Biol* 2004;6:547–54.
36. Honda T, Janosik T, Honda Y, et al. Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxoleano-1,9(11)-dien-28-oic acid for the isolation of the protein targets. *J Med Chem* 2004;47:4923–32.
37. Li L, Shaw PE. A STAT3 dimer formed by inter-chain disulphide bridging during oxidative stress. *Biochem Biophys Res Commun* 2004;322:1005–11.
38. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I κ B kinase. *Nature* 2000;403:103–8.
39. Gharbi S, Garzon B, Gayarre J, Timms J, Perez-Sala D. Study of protein targets for covalent modification by the antitumoral and anti-inflammatory prostaglandin PGA1: focus on vimentin. *J Mass Spectrom* 2007;42:1474–84.
40. Renedo M, Gayarre J, Garcia-Dominguez CA, et al. Modification and activation of Ras proteins by electrophilic prostanoids with different structure are site-selective. *Biochemistry* 2007;46:6607–16.
41. Kim HJ, Kim JY, Meng Z, et al. 15-Deoxy- Δ 12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor- α via covalent modification of DNA-binding domain. *Cancer Res* 2007;67:2595–02.
42. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. *Nat Rev Cancer* 2004;4:97–105.
43. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. *J Biol Chem* 2001;276:45443–55.
44. Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. *Mol Cancer Ther* 2004;3:261–9.
45. Kretschmar AK, Dinger MC, Henze C, Brocke-Heidrich K, Horn F. Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells. *Biochem J* 2004;377:289–97.
46. Gao SP, Bromberg JF. Touched and moved by STAT3. *Sci STKE* 2006;2006:pe30.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Triterpenoid CDDO-Methyl Ester Inhibits the Janus-Activated Kinase-1 (JAK1) → Signal Transducer and Activator of Transcription-3 (STAT3) Pathway by Direct Inhibition of JAK1 and STAT3

Rehan Ahmad, Deepak Raina, Colin Meyer, et al.

Cancer Res 2008;68:2920-2926.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/68/8/2920>

Cited articles This article cites 46 articles, 31 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/68/8/2920.full#ref-list-1>

Citing articles This article has been cited by 13 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/68/8/2920.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/68/8/2920>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.